xpire in 2024. Exelon: The company holds a patent on a specific isomeric form of the active ingredient used in Exelon, which expires in 2014 in the U.S. Exelon Patch is further covered by a formulation patent expiring in 2019 in major markets. The company has filed an infringement lawsuit under its Korean patents. Extavia: The granted Biogen Idec patent would ill expire in September 2026. Comtan: Patent protection for entacapone, the active ingredient in Comtan, which the company licensed from Orion, would expire in the U.S. in 2013. Other patents, such as a polymorph patent, have also been granted. Stalevo: Patent protection for entacapone would expire in the U.S. in 2013. Stalevo is protected by additional patents expiring up to 2020. Integrated Hospital Care Ilaris: Patent protection for the active ingredient in Ilaris is expected to expire in 2024 in the U.S. and in 2024 in Europe. Myfortic: Patents covering the formulation would expire in 2017. Various generic manufacturers have filed applications to market generic versions of Myfortic in the U.S. In Europe, generic manufacturers are seeking approval for generic versions Myfortic in some European countries. Critical Care Xolair: Patent protection for the active ingredient in Xolair would expire in 2018 in the U.S., in 2017 in Europe and in Japan (if the patent term extension pending there is granted). TOBI Podhaler: Patents covering the commercial product would expire from 2018 to 2022 in the U.S. and the EU. Additional patent applications are also pending with respect to the commercial product in the U.S. and the EU. If the last-filed of these applications were granted, then that patent would expire in 2025. In addition, in Europe, the product is entitled to Orphan Drug Status until 2021 for the approved indication. Compounds in Development The company provides the following information regarding its Compounds in Phase III Clinical Development, if any, which have been submitted for registration to the FDA or the EU's European Medicines Agency (EMA): QVA149: Patent protection for indacaterol is expected to expire in 2025 in the U.S. (including patent term extension), in 2024 in Europe (including extensions), and in 2020 in various other markets. In addition, there are patents and patent applications for the combination of indacaterol and glycopyrronium that are due to expire in 2025. RLX030: A patent covering the method of using serelaxin to treat acute heart failure has been granted in the U.S. and expires in 2029. Serelaxin is entitled to post-approval regulatory exclusivity for 12 years in the U.S., 11 years in Europe, and 8 years in Japan. ALCON This division researches, develops, manufactures, distributes, and sells eye care products and technologies to serve the life cycle of eye care needs. This division offers a range of products to treat various eye diseases and conditions, and is organized into three businesses, including Surgical, Ophthalmic Pharmaceuticals, and Vision Care. This division sells products in 180 markets and runs operations in 75 countries. This division works together with the Novartis Institutes for BioMedical Research, the company’s global pharmaceutical research organization. Surgical The company’s Alcon division's Surgical business offers ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses (IOLs) for surgical procedures that address cataracts, vitreoretinal conditions, glaucoma, and refractive errors. Alcon's Surgical portfolio includes the Infiniti vision system to perform cataract surgeries, the Constellation vision system for retinal operations, and the Wavelight refractive suite for refractive procedures. Alcon also offers the AcrySof family of IOLs to treat cataracts, including the AcrySof IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric, and AcrySof IQ ReSTOR Toric IOLs, as well as the LenSx femtosecond laser, a cataract surgery technology that increases precision and reproducibility for the corneal incision, capsulorhexis, and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical